News

Switching from maintenance therapeutic plasma exchange (TPE) to Vyvgart (efgartigimod) appeared to be well tolerated and effective for people with myasthenia gravis (MG), a short report suggests. “The good clinical response of this patient cohort, together with greater accessibility and convenience of infusion-based therapy, are notable advantages…

Dianthus Therapeutics is launching a Phase 2 clinical trial to test its experimental therapy, DNTH103, in people with generalized myasthenia gravis (gMG). Called MaGic, the trial is expected to enroll up to 60 people with gMG who are positive for antibodies that target the acetylcholine receptor (AChR), the…

Curcumin therapy — treatment with the traditional Asian medicine, which is the main ingredient in the spice turmeric — was found to ease disease severity in a mouse model of myasthenia gravis (MG). Use of curcumin, a bright yellow chemical produced by plants, also was shown to normalize microbial…

Higher levels of an immune protein called macrophage migration inhibitory factor (MIF) in the blood are linked to more severe myasthenia gravis (MG) and an increased risk of relapse, according to a study. The findings suggest MIF could be used as a biomarker of MG disease activity, the study’s…

Periocular (around-the-eyeball) injections of triamcinolone, a corticosteroid, may ease early symptoms of ocular myasthenia gravis (MG) and reduce the need for patients to take oral medications that have more potential side effects, a study has found. The study, “A controlled clinical study on efficacy and safety of periocular…

Cour Pharmaceuticals announced that it has raised $105 million in Series A financing to advance its investigational therapy, CNP-106, into a Phase 1b/2a clinical trial as a possible treatment of myasthenia gravis (MG). A company request for clinical testing of CNP-106 was cleared by the U.S.

An under-the-skin, or subcutaneous, injectable formulation of efgartigimod alfa has been approved in the U.K. as an add-on therapy for adults with generalized myasthenia gravis (gMG) who test positive for antibodies against the acetylcholine receptor (AChR). This new formulation will be marketed in the U.K. as Subcutaneous Vyvgart. In…

Nipocalimab, an investigational therapy for people with generalized myasthenia gravis (gMG), significantly eased disease severity compared with a placebo, according to top-line data from a pivotal Phase 3 clinical trial. Johnson & Johnson, the therapy’s developer, also plans to engage with regulatory authorities worldwide to present…

Both high-dose intravenous methylprednisolone (IVMP) and tacrolimus effectively reduced symptom severity in patients with ocular myasthenia gravis (OMG) who failed to respond to oral steroids, a study shows. IVMP began to work quickly and more patients on it achieved a clinically meaningful treatment response over six months. “Both IVMP…

Repeat cycles of Vyvgart (efgartigimod alfa-fcab) led to consistent clinical improvements among generalized myasthenia gravis (gMG) patients, regardless of whether they were positive for antibodies against the acetylcholine receptor, according to interim findings from the ADAPT+ extension study. Given the variability in how many treatment cycles each patient…